{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-24-000015","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.471532+00:00","generated_at":"2026-06-06T01:23:06.296588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth","bullets":["Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).","Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.","Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.","Full year 2023 net loss $255.1M, widened from $166.0M in 2022.","FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-24-000015","json":"https://secwatch.observer/filing/0001770787-24-000015.json","markdown":"https://secwatch.observer/filing/0001770787-24-000015.md","text":"https://secwatch.observer/filing/0001770787-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/0001770787-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/txg-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:23:06.296588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"660034a7d93dea264a022e677823acdb2e86d0ff","claim":"10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.","evidence_excerpt":"10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/0001770787-24-000015-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$184.0 million for the fourth quarter and $618.7 million for the full year of 2023"},{"label":"Net income","value":"Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}